FH Blocking Peptide
Cat# MBS9626808-1mg
Size : 1mg
Brand : MyBiosource
Fh Blocking Peptide – The purity is >90%,tested by HPLC and MS. Purity
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS9626808Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the… More details
Product Overview
Online Datasheet in PDFProduct Name
FH, Blocking Peptide
Full Product Name
FH Blocking Peptide
Product Gene Name
FH blocking peptide
Product Synonym Names
FH; Fumarase; Fumarate hydratase; Fumarate hydratase mitochondrial; Fumarate hydratase, mitochondrial; FUMH_HUMAN; HLRCC; LRCC; MCL; MCUL 1; MCUL1; MS709; Multiple hereditary cutaneous leiomyomata
Form/Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.
Purity/Purification
The purity is >90%,tested by HPLC and MS.
Preparation and Storage
Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.
Antibody/Peptide Pairs
FH peptide (MBS9626808) is used for blocking the activity of FH antibody (MBS9608096)
Molecular Weight
54,637 Da
Chromosome Location
Chromosome: 1; NC_000001.10 (241660857..241683085, complement). Location: 1q42.1
OMIM
136850
Supply Chain Verification
Manufactured in a lab with traceable raw materials manufactured on site. Coordinated product portfolio of antibodies, pairs, conjugates, recombinant proteins, and immunoassay materials available, please inquire.
Notes
For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.
Applications Tested/Suitable for FH blocking peptide
Blocking/Control
Other Notes
Small volumes of FH blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Searchable Terms for FH purchase
MBS9626808 is a blocking peptide targeting FH.
Additional Details
NCBI/Uniprot data below describe general gene information for FH. It may not necessarily be applicable to this product.
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
fumarate hydratase, mitochondrial
NCBI Official Synonym Full Names
fumarate hydratase
NCBI Official Symbol
FH
NCBI Official Synonym Symbols
MCL; LRCC; HLRCC; MCUL1
UniProt Protein Name
Fumarate hydratase, mitochondrial
Protein Family
FH protein interacting protein
UniProt Gene Name
FH
UniProt Synonym Gene Names
Fumarase
UniProt Entry Name
FUMH_HUMAN
NCBI Protein Information
fumarate hydratase, mitochondrial; fumarase
NCBI Summary for FH
The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy. [provided by RefSeq, Jul 2008]
Show more UniProt Comments for FH
FH: a metabolic enzyme that participates in the tricarboxylic acid cycle that catalyzes the conversion of (S)-malate into fumarate + H2O. There are two substrate binding sites: the catalytic A site, and the non-catalytic B site that may play a role in the transfer of substrate or product between the active site and the solvent. Alternatively, the B site may bind allosteric effectors. Fumarate accumulates in the cell when FH is inactivated. Fumarate inhibits the dioxygenases that hydroxylate the transcription factor HIF and leads to its degradation by VHL. Since HIF turns on oncogenic pathways, FH has apparent tumor suppressor activity. Defects in FH are the cause of hereditary leiomyomatosis and renal cell cancer (HLRCC), a highly metastatic form of RCC. Defects in FH are the cause of fumarase deficiency (FD) also known as fumaricaciduria. FD is characterized by progressive encephalopathy, developmental delay, hypotonia, cerebral atrophy and lactic and pyruvic acidemia. Cells derived from a patient with HLRCC exhibit compromised oxidative phosphorylation, dependence on anaerobic glycolysis, rapid glycolytic flux, and overexpression of lactate dehydrogenase A (LDHA) and GLUT1. Two human isoforms are produced by alternative initiation. The longer isoform is mitochondrial, while the shorter form, missing residues 1-43, is cytoplasmic.
Protein type: Lyase; Tumor suppressor; Carbohydrate Metabolism - citrate (TCA) cycle; EC 4.2.1.2; Mitochondrial
Chromosomal Location of Human Ortholog: 1q42.1
Cellular Component: tricarboxylic acid cycle enzyme complex; mitochondrion; mitochondrial matrix; cytoplasm
Molecular Function: fumarate hydratase activity
Biological Process: cellular metabolic process; fumarate metabolic process; tricarboxylic acid cycle; homeostasis of number of cells within a tissue
Disease: Fumarase Deficiency
Show more Protein type: Lyase; Tumor suppressor; Carbohydrate Metabolism - citrate (TCA) cycle; EC 4.2.1.2; Mitochondrial
Chromosomal Location of Human Ortholog: 1q42.1
Cellular Component: tricarboxylic acid cycle enzyme complex; mitochondrion; mitochondrial matrix; cytoplasm
Molecular Function: fumarate hydratase activity
Biological Process: cellular metabolic process; fumarate metabolic process; tricarboxylic acid cycle; homeostasis of number of cells within a tissue
Disease: Fumarase Deficiency
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with FH blocking peptide
| Reference Product | PubMed Publications |
|---|---|
| SDHB blocking peptide | >11 publications with FH and SDHB |
| SDHD blocking peptide | >5 publications with FH and SDHD |
| SDHC blocking peptide | >4 publications with FH and SDHC |
| SOD2 blocking peptide | >3 publications with FH and SOD2 |
| SDHA blocking peptide | >2 publications with FH and SDHA |
| MDH1 blocking peptide | >2 publications with FH and MDH1 |
| MDH2 blocking peptide | >1 publications with FH and MDH2 |
Pathways associated with FH blocking peptide
| Products by Pathway | Pathway Diagram |
|---|---|
| Carbon Metabolism Pathway antibodies | Carbon Metabolism Pathway Diagram |
| Carbon Metabolism Pathway antibodies | Carbon Metabolism Pathway Diagram |
| Citrate Cycle (TCA Cycle) Pathway antibodies | Citrate Cycle (TCA Cycle) Pathway Diagram |
| Citrate Cycle (TCA Cycle) Pathway antibodies | Citrate Cycle (TCA Cycle) Pathway Diagram |
| Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway antibodies | Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway Diagram |
| Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway antibodies | Citrate Cycle, Second Carbon Oxidation, 2-oxoglutarate => Oxaloacetate Pathway Diagram |
| Citric Acid Cycle (TCA Cycle) Pathway antibodies | Citric Acid Cycle (TCA Cycle) Pathway Diagram |
| Conversion Of Glucose To Acetyl CoA And Entry Into The TCA Cycle Pathway antibodies | Conversion Of Glucose To Acetyl CoA And Entry Into The TCA Cycle Pathway Diagram |
| Metabolism Pathway antibodies | Metabolism Pathway Diagram |
| Pathways In Cancer antibodies | Pathways In Cancer Diagram |
Diseases associated with FH blocking peptide
| Disease Name | Pubmed Publications |
|---|---|
| Neoplasms Antibodies | >498 publications with FH and Neoplasms |
| Nervous System Diseases Antibodies | >325 publications with FH and Nervous System Diseases |
| Kidney Diseases Antibodies | >251 publications with FH and Kidney Diseases |
| Brain Diseases Antibodies | >203 publications with FH and Brain Diseases |
| Inflammation Antibodies | >113 publications with FH and Inflammation |
| Adenocarcinoma Antibodies | >90 publications with FH and Adenocarcinoma |
| Hyperplasia Antibodies | >81 publications with FH and Hyperplasia |
| Anemia Antibodies | >70 publications with FH and Anemia |
| Necrosis Antibodies | >68 publications with FH and Necrosis |
| Skin Neoplasms Antibodies | >64 publications with FH and Skin Neoplasms |
Organs/Tissues associated with FH blocking peptide
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Blood Antibodies | >2028 publications with FH and Blood |
| Heart Antibodies | >707 publications with FH and Heart |
| Vascular Antibodies | >435 publications with FH and Vascular |
| Liver Antibodies | >306 publications with FH and Liver |
| Bone Antibodies | >283 publications with FH and Bone |
| Kidney Antibodies | >256 publications with FH and Kidney |
| Brain Antibodies | >239 publications with FH and Brain |
| Skin Antibodies | >190 publications with FH and Skin |
| Muscle Antibodies | >170 publications with FH and Muscle |
| Lung Antibodies | >114 publications with FH and Lung |



